AbbVie to Invest $217 Million in Puerto Rico Biologics Campus, Adding 100 Jobs
AbbVie said Thursday it will invest $217 million to modernize its biologics manufacturing campus in Barceloneta, Puerto Rico, a project that comes with 100 new jobs on the island.
The upgrade will combine advanced manufacturing technologies with artificial intelligence to support production of AbbVie's current and next-generation immunology and neuroscience medicines, the company said in a press release. Work begins this year, and AbbVie expects the facility to be fully operational by 2030.
The new hires will include engineers, scientists, manufacturing operators and lab technicians. AbbVie already employs more than 1,200 people in Puerto Rico and more than 6,000 at its U.S. manufacturing sites, according to the release.
The project counts toward AbbVie's $100 billion commitment to U.S. research and development and capital investments, including manufacturing, over the next decade. With this announcement, the company said it has committed more than $2.4 billion to U.S. manufacturing over the past 16 months, creating more than 1,400 jobs in North Carolina, Arizona, Massachusetts, Illinois and Puerto Rico.
Azita Saleki, AbbVie's executive vice president and chief operations officer, said the investment "reflects our continued commitment to Puerto Rico and to strengthening our U.S. manufacturing network." Puerto Rico Governor Jenniffer González Colón said in the release that it "sends a strong message about Puerto Rico and our ability to compete for high-value manufacturing operations."
By the numbers
- $217 million: new investment in the Puerto Rico biologics campus
- 100: planned new jobs in Puerto Rico
- 2030: target date for the facility to be fully operational
- $100 billion: AbbVie's 10-year U.S. R&D and capital investment commitment
- More than $2.4 billion: AbbVie's U.S. manufacturing commitments over the past 16 months
Sources
- AbbVie Inc. press release, "AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus," Nov. 19, 2026 (AbbVie newsroom)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.